Bank Pictet & Cie Europe AG Purchases 6,050 Shares of Zoetis Inc. $ZTS

Bank Pictet & Cie Europe AG boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 398,610 shares of the company’s stock after purchasing an additional 6,050 shares during the quarter. Zoetis accounts for about 1.2% of Bank Pictet & Cie Europe AG’s investment portfolio, making the stock its 21st biggest holding. Bank Pictet & Cie Europe AG owned about 0.09% of Zoetis worth $58,325,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZTS. Scott & Selber Inc. increased its position in shares of Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after buying an additional 67 shares in the last quarter. North Star Asset Management Inc. grew its stake in Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after acquiring an additional 67 shares during the period. Secure Asset Management LLC grew its stake in Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares during the period. Moment Partners LLC increased its holdings in shares of Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after acquiring an additional 72 shares in the last quarter. Finally, CVA Family Office LLC raised its position in shares of Zoetis by 6.7% during the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after purchasing an additional 74 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZTS shares. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research report on Monday, December 15th. Barclays assumed coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. UBS Group cut their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Finally, BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Price Performance

Shares of NYSE ZTS opened at $125.82 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The business has a 50-day moving average of $125.43 and a 200-day moving average of $142.01. The stock has a market capitalization of $55.45 billion, a price-to-earnings ratio of 21.18, a PEG ratio of 2.73 and a beta of 0.97. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is currently 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.